These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24080973)

  • 1. Urine specimen detection of concurrent nonprescribed medicinal and illicit drug use in patients prescribed buprenorphine.
    Guo AY; Ma JD; Best BM; Atayee RS
    J Anal Toxicol; 2013; 37(9):636-41. PubMed ID: 24080973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new highly specific buprenorphine immunoassay for monitoring buprenorphine compliance and abuse.
    Melanson SE; Snyder ML; Jarolim P; Flood JG
    J Anal Toxicol; 2012 Apr; 36(3):201-6. PubMed ID: 22417836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Illicit drug use correlates with negative urine drug test results for prescribed hydrocodone, oxycodone, and morphine.
    Pesce A; West C; Gonzales E; Rosenthal M; West R; Mikel C; Almazan P; Latyshev S; Horn P
    Pain Physician; 2012; 15(5):E687-92. PubMed ID: 22996862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positivity rates of drugs in patients treated for opioid dependence with buprenorphine: A comparison of oral fluid and urine using paired collections and LC-MS/MS.
    West R; Mikel C; Hofilena D; Guevara M
    Drug Alcohol Depend; 2018 Dec; 193():183-191. PubMed ID: 30391868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definitive urine drug testing in office-based opioid treatment: a literature review.
    Barthwell AG; Allgaier J; Egli K
    Crit Rev Toxicol; 2018 Nov; 48(10):829-852. PubMed ID: 30794024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating medicinal from illicit use in positive methamphetamine results in a pain population.
    West R; Pesce A; West C; Mikel C; Velasco J; Gonzales E; Dizon Z; Almazan P; Latyshev S
    J Anal Toxicol; 2013 Mar; 37(2):83-9. PubMed ID: 23316029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(2):175-87. PubMed ID: 21412372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower Cutoffs for LC-MS/MS Urine Drug Testing Indicates Better Patient Compliance.
    Krock K; Pesce A; Ritz D; Thomas R; Cua A; Rogers R; Lipnick P; Kilbourn K
    Pain Physician; 2017 Nov; 20(7):E1107-E1113. PubMed ID: 29149155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Illicit drug use in the pain patient population decreases with continued drug testing.
    Pesce A; West C; Rosenthal M; Mikel C; West R; Crews B; Almazan P; Latyshev S; Horn PS
    Pain Physician; 2011; 14(2):189-93. PubMed ID: 21412373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs.
    Heltsley R; DePriest A; Black DL; Robert T; Marshall L; Meadors VM; Caplan YH; Cone EJ
    J Anal Toxicol; 2011 Oct; 35(8):529-40. PubMed ID: 22004671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients.
    Pesce A; Rosenthal M; West R; West C; Crews B; Mikel C; Almazan P; Latyshev S
    Pain Physician; 2010; 13(3):273-81. PubMed ID: 20495592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment changes following aberrant urine drug test results for patients prescribed chronic opioid therapy.
    Morasco BJ; Krebs EE; Cavanagh R; Hyde S; Crain A; Dobscha SK
    J Opioid Manag; 2015; 11(1):45-51. PubMed ID: 25750164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database.
    Saloner B; Whitley P; LaRue L; Dawson E; Huskey A
    JAMA Netw Open; 2021 Sep; 4(9):e2123019. PubMed ID: 34505888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids?
    Manchikanti L; Manchukonda R; Pampati V; Damron KS; Brandon DE; Cash KA; McManus CD
    Pain Physician; 2006 Apr; 9(2):123-9. PubMed ID: 16703972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marijuana correlates with use of other illicit drugs in a pain patient population.
    Pesce A; West C; Rosenthal M; West R; Crews B; Mikel C; Almazan P; Latyshev S; Horn PS
    Pain Physician; 2010; 13(3):283-7. PubMed ID: 20495593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretation of urine drug testing results in patients using transdermal buprenorphine preparations for the treatment of chronic noncancer pain.
    Markman JD; Barbosa WA; Gewandter JS; Frazer M; Rast S; Dugan M; Nandigam K; Villareal A; Kwong TC
    Pain Med; 2015 Jun; 16(6):1132-6. PubMed ID: 25800409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients.
    Maremmani I; Pani PP; Pacini M; Perugi G
    J Subst Abuse Treat; 2007 Jul; 33(1):91-8. PubMed ID: 17588494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome.
    Seldén T; Ahlner J; Druid H; Kronstrand R
    Forensic Sci Int; 2012 Jul; 220(1-3):284-90. PubMed ID: 22565115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison between analytic and anamnestic data about drug consumption among opiate addicts with substitutes therapy. A feasibility study].
    Bourgine J; Ma LL; Le Boisselier R; Paillet-Loilier M; Albessard F; Lelong-Boulouard V; Vigneau C; Jolliet P; Debruyne D; Coquerel A
    Therapie; 2009; 64(4):269-77. PubMed ID: 19804707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.